Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of JNJ-88260237 in Healthy Participants
NCT05541315Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AT-20494 in chronic kidney disease (CKD) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events at Day 24, Number of Participants with Abnormalities in Vital Signs at Day 21 and 3 more. Started Sep 2022; status: completed.
02
Drugs
AT-20494
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05541315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05541315.